Varian Gets FDA OK for Ethos Radiotherapy Upgrades

Varian, a Siemens Healthineers company, has gained U.S. Food and Drug Administration (FDA) 510(k) clearance for new functionality to its Ethos radiotherapy system.

Enhanced algorithms now drive the Ethos Intelligence Optimization Engine (IOE) to further optimize treatment planning and dose delivery. Images acquired on Ethos’ HyperSight imaging option are also now integrated into software to enable direct dose calculation and adapt treatments.

Ethos was first launched in 2019. Varian’s data demonstrates that providers treating with Ethos selected the adapted treatment plan 88% of time to be more beneficial for patients. Using Ethos, clinicians can select online or offline adaptation—or conventional image-guided radiotherapy.

The latest version expanded to in 70+ AI-segmented anatomical structures in the head & neck, thorax, abdomen, pelvis, and bowel regions when using HyperSight images. Ethos also now has seamless data sharing and exchange with the ARIA CORE oncology management solution.

Varian said that Ethos 2.0 gives clinical teams a versatile, comprehensive solution, as well as optimizes clinical and operational efficiencies.

“Our latest Ethos system reflects our ongoing commitment to develop innovative solutions that make real-time, adaptive radiotherapy treatment easier to accomplish in any setting,” said Arthur Kaindl, Head of Varian. “By reducing workflow complexity, leveraging advanced, AI-powered technology, and enabling greater connectivity to patient data across our ecosystem, we continue to invest in comprehensive tools to help clinicians integrate precision throughout the patient journey.”